Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Genital Wart
- AIS
- Cervical Cancer
- CIN1
- CIN2
- VIN 2
- VIN 3
- CIN3
- Vaginal Cancer
- VaIN1
- VaIN2
- Vulvar Cancer
- VaIN3
- VIN 1
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Double (Participant, Investigator)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 20 years and 45 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04425291
- Collaborators
- Chongqing Bovax Biopharmaceutical Co., Ltd.
- Investigators
- Not Provided